PG
PCRX icon

PEAK6 Group’s Pacira BioSciences PCRX Stock Holding History

PEAK6 Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,571
Closed -$170K – 4878
2017
Q2 		$170K Buy
+3,571
New +$166K ﹤0.01% 3497
2016
Q1 		– Sell
-9,133
Closed -$534K – 4890
2015
Q4 		$701K Sell
9,133
-22,812
-71% -$1.29M ﹤0.01% 2264
2015
Q3 		$1.31M Buy
31,945
+17,930
+128% +$1.1M 0.01% 1941
2015
Q2 		$991K Buy
+14,015
New +$1.1M 0.01% 2098
2014
Q2 		– Sell
-10,534
Closed -$737K – 5003
2014
Q1 		$737K Buy
+10,534
New +$716K 0.01% 2148
2013
Q4 		– Sell
-49,336
Closed -$1.19M – 5313
2013
Q3 		$1.19M Buy
+49,336
New +$1.8M 0.01% 2007

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return